46 results about "Anti-idiotypic antibodies" patented technology

A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too.

The invention relates, among other things, a preparation comprising Alzheimer's disease antigen (A68), as well as methods of obtaining this purified antigen, and methods of using this purified antigen, for instance, for diagnosing Alzheimer's disease and for detecting human autoantibodies to the Alzheimer disease antigen. The antigen preparation according to the invention is purified in that it is substantially free of immunoglobulin G. The invention further relates to methods of making Alzheimer disease antigens that can be used instead of or along with the A68 antigen preparation (e.g., for diagnosing AD), such as recombinant human tau, tau isolated from various species including human, and phosphorylated recombinant human tau or isolated tau, as well as A68 anti-idiotypic antibodies.

The presence and quantity of an antibody of interest in a patient's bloodstream or other biological sample can serve as an important clinical or other analytical or diagnostic tool. ELISA methods, and kits for such assays, as well as anti-idiotypic antibodies and hybridomas producing them, are developed to detect levels of the antibody in biological samples, which are from, for example, animal models and human patients.

The invention relates to Ab2-type anti-idiotypic antibodies and fragments thereof which mimic HVI-1 epitopes that are otherwise cryptic to the immune system and which antibodies or fragments thereof are directed against potently neutralizing anti-HIV-1 antibodies. The invention further relates to a hybridoma cell line 3H6 expressing the anti-idiotypic antibody and to pharmaceutical compositions containing the antibody or fragment thereof. The invention also relates to HIV-1 neutralizing Ab3-type antibodies elicited upon administration of the Ab2-type anti-idiotypic antibody or fragment thereof and to pharmaceutical compositions containing them. The invention also relates to the use of the present antibodies or fragments thereof as screening tools or as diagnostic or therapeutic agents.

The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the domain A2 of Factor VIII, and to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as drug, and more particularly, to its use for the manufacturing of a drug to be used for the treatment of haemophilia A.

Vaccines capable of eliciting an immune antitumor response for prostate tumors are disclosed. The active ingredient in such vaccines is selected from the group consisting of at least one antigen over-represented in the prostate gland or an immunologically effective portion thereof; an expression system capable of generating in situ said antigen or portion; a naked DNA encoding such antigen and portion; and an anti-idiotypic antibody or fragment thereof which mimics said antigen or portion.

In vivo methods for making anti-idiotypic antibodies and compositions comprising the antibodies.

The invention belongs to the field of molecular biology, and particularly relates to an application of an ochratoxin A anti-idiotypic nano-antibody used as a ochratoxin A standard substitute. The present invention obtains the ochratoxin A anti-idiotypic nano-antibody with an amino acid sequence shown in SEQ ID NO: 1. According to ELISA standard curves of standard ochratoxin A and an ochratoxin A anti-idiotypic antibody, under the same inhibition ratio, corresponding relationship curves of the concentration of the ochratoxin A and the concentration of the ochratoxin A anti-idiotypic antibody are established. Besides, the results are subjected to exponential regression analysis to obtain a corresponding relationship between the the ochratoxin A and the ochratoxin A anti-idiotypic antibody. The corresponding relationship can be applied to the detection and analysis of ochratoxin A in agricultural products. The immunodetection method that the ochratoxin A anti-idiotypic nano-antibody replaces the standard ochratoxin A has accurate and reliable results, and is an effective and feasible method for green immunoassay.

A method for identifying molecules which mimic an idiotype of an autoimmune disease-associated auto-antibody (autoantibodies). The method comprises the following steps: (a) purifying autoantibodies from sera of one or more patients afflicted with the autoimmune disease; (b) binding the autoantibodies to a solid phase to form an affinity matrix; (c) contacting pooled plasma or B cells comprising immunoglobulins with the affinity matrix followed by removal of unbound plasma components; (d) eluting bound immunoglobulins, being anti-Idiotypic antibodies (anti-Id) to autoantibodies, from the matrix; (e) providing a molecular library comprising a plurality of molecule members; and (e) contacting the anti-Id with the molecular library and isolating those bound molecules which are bound by the anti-Id, the bound molecules being molecules which mimic an idiotype of autoantibodies. Also disclosed are such molecules.

Peptides generated from a random library that are bound by a monoclonal antibody to Chlamydial glycolipid exoantigen (GLXA) and thus mimic this antigen are disclosed. Peptides that correspond to antigen-binding regions of an anti-idiotypic antibody (mAb2) specific for anti-GLXA antibody (Ab1) which act as molecular mimics of GLXA are also disclosed used as immunogens to induce broadly reactive genus-specific anti-chlamydial antibodies. These peptides and immunogenic DNA encoding the mAb2-like peptides, microparticle or nanoparticle formulations and other formulations of these peptides are disclosed as are methods for immunizing subjects to obtain genus-specific anti-chlamydial antibodies and to treat or prevent Chlamydia-associated or induced rheumatoid arthritis.

The present invention relates to an anti-idiotypic antibody and applications thereof, particularly to an anti-idiotypic antibody specifically for influenza virus B broad-spectrum neutralizing monoclonal antibody (such as monoclonal antibody 11B10), a cell strain capable of producing the anti-idiotypic antibody, a preparation method of the anti-idiotypic antibody, and a composition (such as a pharmaceutical composition or a vaccine) containing the anti-idiotypic antibody, and further provides uses of the anti-idiotypic antibody. According to the present invention, the anti-idiotypic antibody can be used for prevention and/or treatment of influenza virus infections and/or diseases caused by the infections (such as influenza).

The present invention relates to neutralizing anti-HIV-1 antibodies, particularly to mAb 4E10-IgG1, which has an HIV-1 neutralizing potency comparable to the one of mAb 2F5 and 2G12. 4E10-IgG1 binds to a novel conserved epitope (NWFDIT) C-terminal of the ELDKWA epitope recognized by 2F5.1 appears that both epitopes are cryptic epitopes within a region that may be accessible in a virus-cell fusion intermediate state only. 4E10-IgG1 potently neutralizes tissue culture adapted strains but also primary isolates of different clades, including A, B, C, D, and E, inclusing viruses that were found to be resistant to 2F5. None of the tested isolates was resistant to both anti-gp41-antibodies. The invention therefore also relates to peptides containing the 4E10 epitope and to compositions made thereof, as well as to anti-idiotypic antibodies that are reactive with the paratope of 4E10-IgG1, to compositions containing an antiidiotypic antibody optionally in combination with a peptide containing the 4E10 epitope, and to anti-HIV-1 compositions comprising 4E10-IgG1, optionally in combination with another neutralizing antibody such as 2F5 and/or 2G12.

A polynucleotide, comprising a contiguous nucleotide sequence coding for a human antibody with factor VIII specificity, or complementary to a nucleotide sequence coding for a human antibody for factor VIII specificity, or capable of selectively hybridizing under stringent conditions to such nucleotide sequence. Such polynucleotide may be used as a probe or primer for detection of factor VIII inhibitors, or be used for producing a recombinant polypeptide. A polypeptide, comprising a contiguous amino acid sequence corresponding to or mimicking a fragment or derivative of a human antibody with factor VIII specificity capable of specific binding to factor VIII. An antibody, comprising a recombinant human antibody with factor VIII specificity or an anti-idiotypic antibody directed against a human antibody with factor VIII specificity. Pharmaceutical compositions which contain such polypeptide or antibody.

The present invention relates to a schistosoma japonicum monoclonal anti-idiotypic antibody NP30 monospecific diabody and a preparation method and applications thereof., which belong to the field of genetic engineering technology and immunotherapy drug preparation. The preparation method utilizes the genetic engineering technology to prepare the schistosoma japonicum monoclonal anti-idiotypic antibody NP30 monospecific diabody and adopts overlap PCR to amplify diabody gene VH-linker-VL (diabody, D for short), the length of linker chooses five amino acid residues, the sequence is GGGGS, and two scFv molecules are forced to mutually form VH-VL pairing, and bound together by a non-covalent bond to form a dipolymer, which is called diabody. The diabody can be used to treat acute schistosome infection and immunoprotection against schistosomiasis.

The invention provides a genetic engineering vaccine for an anti-idiotypic antibody of edwardsiella tarda and a method for preparing the same. The method comprises the following steps: adopting an RT-PCR method to clone VH and VL variable region genes from a hybridoma cell strain which excretes idiotype monoclonal antibodies of the edwardsiella tarda; introducing a connecting peptide (Gly4Ser)3 into the VH and VL variable region genes; constructing a single chain antibody scFv gene in the form of VL-Linker-VH in vitro, and cloning the single chain antibody scFv gene to an expression vector PET28a and expressing the same in Escherichia coli; and after purifying expressed product, identifying the product through SDS-PAGE, Western blot and ELASA: expressing an anti-idiotypic single chain antibody gene scFv of the edwardsiella trada in a BL21 bacterium, preserving the expressed product in the form of an insoluble inclusion body, obtaining a high purity single chain antibody fragment by dissolving the inclusion body, purifying, and renaturing in vitro. The relative molecular weight of the recombinant protein is 27 kD. The immune protection rate for sea fishes is averagely more than 80 percent.